Mabwell Biotech

Mabwell (Shanghai) Bioscience Co., Ltd. (SSE: 688062) is an integrated biopharmaceutical firm engaged in the research, development, manufacturing, and commercialization of therapeutic biological products. Established in 2017 and headquartered in Shanghai's Zhangjiang Hi-Tech Park, the company has expanded by acquiring and setting up nine additional biopharmaceutical research and production entities. A significant milestone was achieved in January 2022 when Mabwell was listed on the STAR Market of the Shanghai Stock Exchange, raising approximately $547 million. The company is led by co-founder, Chairman, and General Manager Dr. Datao Liu, who has over 20 years of experience in the R&D and industrialization of novel biologics.

The company's business model is centered on developing and selling innovative drugs and biosimilars, with a product portfolio that includes monoclonal antibodies, antibody-drug conjugates (ADCs), and recombinant proteins. Mabwell's revenue is primarily generated from product sales, research services for other biotech firms, and licensing collaborations. The company has a comprehensive R&D system that covers the entire process from target discovery to manufacturing transformation. It operates manufacturing facilities in Taizhou and Shanghai, which are compliant with international GMP standards, to meet the demands of its expanding pipeline. Mabwell also has a U.S.-based subsidiary, Mabwell Therapeutics, located in San Diego, which focuses on developing therapies for rare diseases.

Mabwell has a robust pipeline of 16 products, including 12 novel drug candidates and 4 biosimilars. Its therapeutic focus areas are extensive, covering oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases. Several products have already been commercialized, such as MAIWEIJIAN for giant cell tumors of bone, MALISHU for osteoporosis, and JUNMAIKANG, an adalimumab biosimilar. The pipeline includes promising candidates like 7MW4911, a CDH17-targeting ADC for gastrointestinal cancers, and 9MW2821, a Nectin-4 targeting drug for cervical cancer. Mabwell actively pursues global commercialization through licensing agreements, such as those with Disc Medicine and UNILAB.

Keywords: biopharmaceutical, antibody drug development, monoclonal antibodies, antibody-drug conjugates, oncology therapeutics, immunology drugs, biosimilars, clinical trials, GMP manufacturing, STAR market, biologics commercialization, rare disease therapeutics, ophthalmology drugs, bone disorder treatment, recombinant proteins, drug discovery, ADC technology, cancer research, autoimmune diseases, cell therapy